# Disease Progression Rate Parameters ‚Äî Literature Review

**Review Date:** February 22, 2026  
**Reviewer:** Anton üî¨  
**Cron Job:** 5a07cbd2-78af-4cbd-97e3-1fe6041678ff

---

## Overview

This literature review examines three critical disease progression rate parameters in the SSWD-EvoEpi model:

1. **mu_EI1_ref** ‚Äî E‚ÜíI‚ÇÅ progression rate at T_ref (d‚Åª¬π)
2. **mu_I1I2_ref** ‚Äî I‚ÇÅ‚ÜíI‚ÇÇ progression rate at T_ref (d‚Åª¬π)  
3. **mu_I2D_ref** ‚Äî I‚ÇÇ‚ÜíDeath rate at T_ref (d‚Åª¬π)

These parameters control the temporal dynamics of the S‚ÜíE‚ÜíI‚ÇÅ‚ÜíI‚ÇÇ‚ÜíD disease cascade for sea star wasting disease (SSWD) caused by *Vibrio pectenicida* in *Pycnopodia helianthoides*.

---

## mu_EI1_ref: Exposed to First Infectious Stage Rate

### Description
Rate at which exposed individuals progress from the incubation period (E) to early symptomatic disease (I‚ÇÅ). This represents the inverse of the mean incubation period‚Äîthe time from pathogen exposure to first visible symptoms.

### First Principles
- **Mechanistic meaning**: Speed of *V. pectenicida* establishment and initial host tissue damage
- **Physical constraints**: Must be >0; extremely high values (>2.0 d‚Åª¬π) would eliminate incubation period entirely
- **Biological bounds**: Incubation periods <12 hours unlikely (bacterial establishment takes time); >2 weeks may allow immune clearance
- **Disease cascade requirement**: If too fast, E compartment becomes negligible; if too slow, epidemic cannot establish
- **Expected range**: 1/(1-14 days) = 0.07-1.0 d‚Åª¬π

### Literature Evidence
- **Temperature sensitivity established**: Bates (2009) showed 4¬∞C temperature increase sufficient to induce SSWD-like symptoms within 96 hours, indicating rapid progression at elevated temperatures
- **Clinical observations**: Laboratory outbreak described symptoms developing "over the course of a week" (Wikipedia, citing marine lab observations)
- **Mechanism**: McCracken et al. (2025) showed immune system activation and tissue homeostasis disruption **precede** visible wasting symptoms, consistent with an incubation period where pathogen establishment occurs before clinical signs

### Recommended Values
- **Recommended value**: 0.57 d‚Åª¬π (‚âà1.8 days mean incubation)
- **SA range**: 0.20-1.00 d‚Åª¬π (1-5 days mean incubation)
- **Confidence**: MEDIUM ‚Äî indirect evidence from temperature studies and clinical observations
- **Key sources**: Bates (2009), McCracken et al. (2025), marine laboratory observations

---

## mu_I1I2_ref: First to Second Infectious Stage Rate

### Description
Rate at which individuals progress from early symptomatic disease (I‚ÇÅ) to severe wasting disease (I‚ÇÇ). This captures disease escalation from initial lesions/lethargy to advanced tissue breakdown.

### First Principles
- **Mechanistic meaning**: Speed of *V. pectenicida* proliferation and aerolysin-like toxin damage escalation
- **Physical constraints**: Must be >0; extremely high values would eliminate I‚ÇÅ stage entirely
- **Biological bounds**: Very rapid progression (>1.0 d‚Åª¬π) inconsistent with observed clinical course; very slow progression (<0.1 d‚Åª¬π) inconsistent with acute nature of SSWD
- **Disease cascade requirement**: I‚ÇÅ‚ÜíI‚ÇÇ transition must be faster than recovery to maintain epidemic character
- **Expected range**: Similar to mu_EI1_ref, approximately 0.2-1.0 d‚Åª¬π

### Literature Evidence
- **Temperature dependence**: Kohl et al. (2016) demonstrated that cooler temperatures (9.0¬∞C vs 12.1¬∞C) **slow disease progression** but do not prevent mortality, indicating this parameter is temperature-sensitive
- **Disease stages observed**: Clinical descriptions include progression from lethargy ‚Üí lesions ‚Üí tissue breakdown ‚Üí arm autotomy, consistent with a multi-stage process
- **Pathogen mechanism**: Zhong et al. (2025) identified aerolysin-like toxin genes in *V. pectenicida* FHCF-3, providing mechanism for progressive tissue damage

### Recommended Values
- **Recommended value**: 0.40 d‚Åª¬π (‚âà2.5 days mean duration of I‚ÇÅ)
- **SA range**: 0.15-0.80 d‚Åª¬π (1.25-6.7 days mean I‚ÇÅ duration)
- **Confidence**: LOW ‚Äî limited direct evidence, inferred from clinical progression descriptions
- **Key sources**: Kohl et al. (2016), Zhong et al. (2025), clinical stage descriptions

---

## mu_I2D_ref: Second Infectious Stage to Death Rate

### Description
Rate at which severely wasted individuals (I‚ÇÇ) die from SSWD. This represents the final, lethal phase of the disease cascade.

### First Principles
- **Mechanistic meaning**: Speed of terminal organ failure and death from *V. pectenicida* infection
- **Physical constraints**: Must be >0; if too high (>0.5 d‚Åª¬π), I‚ÇÇ stage becomes very brief; if too low (<0.05 d‚Åª¬π), inconsistent with SSWD lethality
- **Biological bounds**: Terminal phase typically 2-20 days based on general infectious disease patterns
- **Disease cascade requirement**: Must be high enough to generate significant mortality but not so high as to eliminate I‚ÇÇ compartment
- **Expected range**: 0.05-0.5 d‚Åª¬π (2-20 days mean survival in I‚ÇÇ)

### Literature Evidence
- **High lethality established**: Kohl et al. (2016) found 100% mortality in both temperature treatments (9.0¬∞C and 12.1¬∞C), confirming SSWD is highly lethal
- **Terminal progression**: Clinical descriptions indicate rapid deterioration once severe wasting begins, with "death and rapid disintegration"
- **Population-level evidence**: Harvell et al. (2019) documented >90% population crashes during 2013-2014 outbreak, indicating very high case fatality rates
- **Recovery rare**: Observations of recovery from severe SSWD are extremely rare in the literature

### Recommended Values
- **Recommended value**: 0.173 d‚Åª¬π (‚âà5.8 days mean survival in I‚ÇÇ)
- **SA range**: 0.08-0.35 d‚Åª¬π (2.9-12.5 days mean I‚ÇÇ survival)
- **Confidence**: MEDIUM ‚Äî strong evidence for high lethality, moderate evidence for timing
- **Key sources**: Kohl et al. (2016), Harvell et al. (2019), clinical observations

---

## Synthesis and Model Implications

### Parameter Relationships
The three rates together control the **shape** of the disease time course:
- **Fast mu_EI1_ref + moderate mu_I1I2_ref + slow mu_I2D_ref** ‚Üí Long infectious period, chronic disease
- **All rates fast** ‚Üí Acute die-off with brief infectious period  
- **Slow mu_EI1_ref + fast later rates** ‚Üí Long incubation, rapid terminal progression

### Temperature Dependence
All three parameters show Arrhenius temperature dependence in the model:
- **Established empirically**: Bates (2009), Kohl et al. (2016) demonstrate clear temperature effects
- **Mechanistic basis**: *Vibrio* species are known to be temperature-sensitive; warmer conditions favor bacterial growth and toxin production
- **Model implementation**: Parameters scaled by `arrhenius(rate_ref, Ea, T_celsius)` function

### Uncertainty and Sensitivity
- **Highest uncertainty**: mu_I1I2_ref due to difficulty distinguishing I‚ÇÅ from I‚ÇÇ stages in clinical observations
- **Sensitivity analysis priority**: All three parameters identified as important in Morris R4 screening
- **Critical constraint**: Total disease time (1/mu_EI1_ref + 1/mu_I1I2_ref + 1/mu_I2D_ref) must be consistent with observed "days to weeks" progression

### Research Priorities
1. **Controlled infection experiments** with *V. pectenicida* FHCF-3 using Koch's postulates protocol
2. **Time-series sampling** of infected individuals with frequent health assessments
3. **Temperature manipulation studies** to quantify Arrhenius parameters
4. **Biomarker development** to distinguish E, I‚ÇÅ, and I‚ÇÇ stages objectively

---

## Data Gaps and Limitations

### Critical Gaps
- **No controlled progression studies**: Despite breakthrough pathogen identification (Aquino/Prentice 2025), no published studies track individual disease progression with precise timing
- **Stage definitions subjective**: I‚ÇÅ vs I‚ÇÇ distinction based on clinical appearance, not objective biomarkers
- **Species-specific data**: Most quantitative studies on *Pisaster ochraceus*; *Pycnopodia helianthoides* data limited

### Literature Limitations
- **Historical studies** pre-date pathogen identification, limiting mechanistic interpretation
- **Field studies** cannot control for exposure timing, confounding progression rate estimates
- **Laboratory studies** often use already-diseased animals, precluding incubation period measurement

### Model Assumptions
- **Exponential transitions**: Real disease progression may be more complex (sigmoidal, multi-modal)
- **Temperature independence of stages**: Model assumes same Arrhenius parameters for all individuals
- **No recovery from I‚ÇÇ**: Model assumes I‚ÇÇ‚ÜíD transition is irreversible

---

## Confidence Assessment

| Parameter | Confidence | Reasoning |
|-----------|------------|-----------|
| mu_EI1_ref | MEDIUM | Temperature sensitivity established; approximate timing from field observations |
| mu_I1I2_ref | LOW | Limited ability to distinguish I‚ÇÅ from I‚ÇÇ objectively; inferred from progression descriptions |
| mu_I2D_ref | MEDIUM | High lethality well-documented; moderate evidence for terminal phase timing |

**Overall confidence**: MEDIUM-LOW ‚Äî parameters are reasonable for modeling purposes but would benefit significantly from controlled experimental validation.